High Implantation of Self-Expanding Valves in the Aortic Position or Cusp Overlapping: Should It Be the New “Gold Standard”?

Transcatheter aortic valve replacement (TAVR) has been proving its benefit in different scenarios for two decades now. However, in the field of self-expanding valves, one challenge has always been its high rate of pacemaker implantation compared with balloon-expandable devices and valvular replacement surgery.

Implante alto de las válvulas autoexpandibles en posición aórtica

For this reason, the high implantation or Cusp Overlapping strategy was developed. This alternative has demonstrated in different analyses a lower need for definitive pacemaker after implantation, but to date there are only small studies and no randomized or large studies.

Researchers conducted a meta-analysis of 11 (non-randomized) studies, which included 3207 patients. Of them, 1464 (45.6%) had a Cusp Overlapping (COVL), while 1743 had a tricuspid coplanar implantation (COP).

The primary endpoint (PEP) was permanent pacemaker implantation.

The PEP was in favor of the COVL group (odds ratio: 0.48; 95% confidence interval [CI]: 0.33-0.70; p = 0.001). Among these patients, there was also a higher implant compared with the COP group (mean difference: -0.83; 95% CI: -1.2 to -0.45; p < 0.001).

Read also: Drug-Eluting Balloon in STEACS: Leaving No Trace is Beneficial?

There was no statistically significant difference regarding the presence of new left bundle branch block, moderate or severe paravalvular leak, need for a second valve, stroke, mortality, crossover to surgery, coronary obstruction, and gradient after implantation.

Conclusion

In TAVR with self-expandable valves, implantation with COVL was associated with lower risk of definitive pacing compared with the COP strategy, with no increased risk of adverse events.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Cusp‐overlap versus coplanar view in transcatheter aortic valve implantation with self‐expandable valves: A meta‐analysis of comparative studies.

Reference: Michel Pompeu Sá, et al. Catheter Cardiovasc Interv. 2023;101:639–650.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...